Comparative Pharmacology
Head-to-head clinical analysis: TOLMETIN SODIUM versus ZIPSOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TOLMETIN SODIUM versus ZIPSOR.
TOLMETIN SODIUM vs ZIPSOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. It has anti-inflammatory, analgesic, and antipyretic effects.
Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis involved in inflammation, pain, and fever. It has no significant inhibition of COX-1 at therapeutic doses.
400 mg orally three times daily; maximum 1800 mg/day.
50 mg orally three times daily
None Documented
None Documented
Terminal elimination half-life is approximately 4.5–6 hours (mean 5 hours); may be prolonged in elderly or patients with renal impairment
2-4 hours (terminal); clinical context: short half-life necessitates frequent dosing for sustained relief; prolonged in hepatic impairment
Renal excretion (~90% as unchanged drug and conjugates), with fecal excretion (~10% as metabolites)
Renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; remainder as glucuronide conjugates
Category D/X
Category C
NSAID
NSAID